F-18 florbetaben, also known as Neuraceq, received U.S. Food and Drug Administration (FDA) approval today as a diagnostic amyloid agent to help rule out Alzheimer’s disease.  The news comes on the heels of the agent’s European Commission green light a month ago to market the drug in Europe. The PET agent is used to approximate the density of amyloid plaque in the brain for cognitively impaired patients suspected to be developing Alzheimer’s disease and other neurodegenerative disorders.{read more here}